Mutations Associated with No Durable Clinical Benefit to Immune Checkpoint Blockade in Non-S-Cell Lung Cancer

Mutations Associated with No Durable Clinical Benefit to Immune Checkpoint Blockade in Non-S-Cell Lung Cancer

(1) Background: The immune checkpoint blockade (ICB) has shown promising efficacy in non-small-cell lung cancer (NSCLC) patients with significant clinical benefits and durable responses, but the overall response rate to ICBs is only 20%. The lack of responsiveness to ICBs is currently a central prob...

Full description

Bibliographic Details
Main Authors: Guangsheng Zhu, Dian Ren, Xi Lei, Ruifeng Shi, Shuai Zhu, Ning Zhou, Lingling Zu, Ramon Andrade De Mello, Jun Chen, Song XU
Format: Article
Language:English
Published: MDPI AG 2021-03-01
Series:Cancers
Subjects:
non-small cell lung cancer
immunotherapy
KEAP1
FAT1
PD-1/PD-L1 inhibitors
anti-PD1/PD-L1
Online Access:https://www.mdpi.com/2072-6694/13/6/1397

Similar Items

Similar Items